Enhancing Adoptive CD8 T Cell Therapy by Systemic Delivery of Tumor Associated Antigens

Scientists showed that systemic delivery of tumor-associated antigens facilitated in vivo priming and expansion of previously non-activated T cells and enhanced the cytotoxicity of activated T cells.